Plant Insulation Co. Asbestos Settlement Trust Claims

Plant Insulation Asbestos Trust Facts

Bankruptcy and Trust History

The official Trust states that the Plant Insulation Company Asbestos Settlement Trust was established pursuant to an order of the U.S. Bankruptcy Court for the Northern District of California, San Francisco Division, under special provisions of the Bankruptcy Code to accept and resolve asbestos claims arising from Plant Insulation Company operations.

The 2025 annual report identifies the bankruptcy proceeding as Case No. 09-31347-HLB. It cites the Amended and Restated Second Amended Plan filed April 2, 2012, the April 3, 2012 confirmation order, later plan modifications, and the March 3, 2014 modified confirmation order.

The Trust is governed by its Trust Agreement, Bylaws, Trust Distribution Procedures and Case Valuation Matrix. Historical insurance settlements or other funding arrangements are not presented as current assets; current assets are reported separately from the Trust’s audited 2025 financial statements.

Who May Qualify for a Plant Insulation Claim?

The current Matrix recognizes Mesothelioma, Lung Cancer, Other Cancer, Grade I Non-Malignancy and Grade II Non-Malignancy. Eligibility and valuation depend on disease, medical evidence, Plant exposure, exposure rating and duration, age, living status, economic loss, medical expenses and other Matrix factors.

The Trust’s current claims packet provides separate checklists for Mesothelioma, Lung Cancer, Other Cancer, Grade I, Grade II, Enhanced and Serious Asbestosis claims. It also provides approved site information, traditional occupation information, claim forms and supporting-document requirements.

Case Valuation and Disease Values

The Matrix included with the 2025 annual report publishes the following base case values and Plant several-share Average Values:

These are not guaranteed settlement or payment amounts. The Matrix increases or decreases a base value using claim-specific factors. For mesothelioma, for example, exposure ratings range from Very Low through Very High, with published multipliers from 0.25 to 3.0. Age, whether the injured person is living, dependents, economic loss and medical expenses can also affect valuation.

For payments made during 2026, the annual report confirms a 37.99% cumulative inflation adjustment. It also reports 2026 indexed base amounts of $275,975 for Economic Loss, $263,286 for Medical Loss, and $98,732 for Assumed Future Medical Loss and Funeral Expenses.

Need help now? Call 800.291.0963
Live chat available 24/7, 365 days a year.
Submit Your Case

Current 20% Funds Received Ratio

Plant uses the term Funds Received Ratio rather than a conventional Payment Percentage. The Trustees increased the ratio from 16.5% to 20% in 2024 with the consent of the Trust Advisory Committee and Futures Representative. The 2025 annual report confirms that, as of December 31, 2025, Trust Claims were paid at the approved 20% ratio.

The audited financial-statement notes record the progression from 11.5% in May 2019, to 16.5% in April 2023, to 20% in April 2024, and state that the 20% increase was retroactive for claims paid since inception.

Mathematical illustration only — not a guaranteed payment. A simple $512,799 mesothelioma base value × 20% equals $102,559.80 before considering the Matrix’s claim-specific multipliers, applicable inflation adjustment and other rules. Because actual Plant claims are individually valued under the Matrix, this calculation is not a claim estimate or promised payment.

Claim Filing and Valuation Procedures

The Trust accepts claims electronically or by mail and provides the critical filing documents on its official claims page. Each valid claim is assigned a liquidated value under the Matrix and TDP based on its compensable disease and claim-specific facts.

The TDP establishes processing and payment procedures, Maximum Annual Payment controls, a Funds Received Ratio, claims-audit rules, second-disease claims, dispute procedures and other safeguards. The 2025 annual report states that the filing fee remained $250 after review at the November 7, 2025 Trustees’ meeting.

The Trustees set the 2026 Maximum Annual Payment at $10,472,086. This is a Trust-wide annual payment-management limit and is not a maximum award for one claimant.

Medical and Exposure Requirements

The Matrix requires a 10-year latency period between first asbestos exposure and diagnosis for mesothelioma and other specified disease categories. Medical proof varies by disease and can require reports from a pathologist, internist, pulmonologist or occupational medicine physician, together with appropriate imaging, pathology or pulmonary-function evidence.

For a mesothelioma Matrix claim, the current Matrix generally requires Plant exposure totaling at least three months or at least 10% of the injured person’s total asbestos exposure. A mesothelioma claimant establishing at least one month but less than three months of qualifying Plant exposure may receive a reduced liquidated value under the Matrix.

For other compensable disease categories, the Matrix generally requires Plant exposure totaling at least one year or at least 25% of total asbestos exposure; qualifying exposure of at least three months but less than one year may result in reduced valuation. Exposure at multiple sites may be aggregated under the Matrix rules.

The official site also maintains an approved site list that may be modified as additional evidence and claim-processing experience become available.

2025 Financial and Claims Information

The Fourteenth Annual Report includes audited financial statements for the year ended December 31, 2025. The statements report $162,379,512 in total assets, $13,554,726 in total liabilities and $148,824,786 in net claimants’ equity.

The official 2025 Claim Report states that the Trust received 549 claims, issued offers to 552 claimants and paid 354 claims. Paid claims included 53 mesothelioma, 54 lung cancer, 12 other cancer, 33 Grade I Serious Asbestosis, 111 other Grade I/Enhanced Asbestosis and 91 Grade II Non-Malignant claims.

The Claim Report states that total claims paid since inception were $191,680,841 through December 31, 2025 for trust-processed, pre-petition and increase payments.

Payments made on Trust Claims during 2025 included a 34.49% cumulative CPI-W inflation adjustment. For 2026 payments, the annual report confirms that the cumulative inflation adjustment increased to 37.99%.

Confirmed Primary Sources for Trust Facts

No law-firm or lead-generation website was used as factual authority for this page. Primary Trust and bankruptcy materials reviewed include:

• Official Plant Asbestos Settlement Trust website.
• Official About the Trust page.
• Official current Trust Documents library.
• Official claims packet and filing materials.
• Official 2024 Funds Received Ratio notice.
• Official annual-report archive.
• Fourteenth Annual Report and Accounting, Audited Financial Statements, and Claim Report for 2025, filed April 28, 2026.

Get Help Reviewing a Plant Insulation Asbestos Claim

Call 800.291.0963

Live chat is available 24/7, 365 days a year.

Submit Your Case

Prior asbestos exposure does not automatically establish eligibility for a Plant Insulation trust claim or asbestos lawsuit. Eligibility and valuation depend on medical evidence, exposure history, current Trust procedures, the Case Valuation Matrix and individual circumstances. Compensation is not guaranteed.